Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Four drug-sensitive subunits are required for maximal effect of a voltage sensor-targeted KCNQ opener.

The Journal of general physiology - 1 Oct 2018

Wang Alice W, Yau Michael C, Wang Caroline K, Sharmin Nazlee, Yang Runying Y, Pless Stephan A, Kurata Harley T

Abstract excerpt

KCNQ2-5 (Kv7.2-Kv7.5) channels are strongly influenced by an emerging class of small-molecule channel activators. Retigabine is the prototypical KCNQ activator that is thought to bind within the pore. It requires the presence of a Trp side chain that is conserved among retigabine-sensitive channels but absent in the retigabine-insensitive KCNQ1 subtype. Recent work has demonstrated that certain KCNQ openers are...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to KCNQ1 gene
Share to KCNQ2 gene

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to KCNQ3 gene

Share to HEK293 Cells

Share to KCNQ Potassium Channels

Share to Mutation

Source

Open in PubMed Open full text

Identifiers

PMID: 30166313
DOI: 10.1085/jgp.201812014
PMCID: PMC6168237

Genes

KCNQ2
KCNQ1
KCNQ3

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Four drug-sensitive subunits are required for maximal effect of a voltage sensor-targeted KCNQ opener.PMID 30166313Read ↗

One drug-sensitive subunit is sufficient for a near-maximal retigabine effect in KCNQ channels.Semantic proximity Read ↗

Sequence determinants of subtype-specific actions of KCNQ channel openers.Semantic proximity Read ↗

Functional screen for subtype specificity of voltage sensor-targeted Kv7 potentiators.Semantic proximity Read ↗

Potent KCNQ2/3-specific channel activator suppresses in vivo epileptic activity and prevents the development of tinnitus.Semantic proximity Read ↗

Synthesis and Pharmacological Characterization of Conformationally Restricted Retigabine Analogues as Novel Neuronal Kv7 Channel Activators.Semantic proximity Read ↗

Site and Mechanism of ML252 Inhibition of Kv7 Voltage-Gated Potassium Channels.Semantic proximity Read ↗

Functional control of heteromeric Kv2.1/6.4 channels by the voltage sensor domain of the silent Kv6.4 subunit.Semantic proximity Read ↗

Personalized treatment with retigabine for pharmacoresistant epilepsy arising from a pathogenic variant in the KCNQ2 selectivity filterSemantic proximity Read ↗

The KCNQ2/3 selective channel opener ICA-27243 binds to a novel voltage-sensor domain site.Semantic proximity Read ↗

Structural Basis for the Modulation of Human KCNQ4 by Small-Molecule Drugs.Semantic proximity Read ↗

Discovery of Kv3.1 channel inhibitors reveals VU0521426 as a state-dependent inactivator preferentially active against pathogenic gain-of-function mutants.Semantic proximity Read ↗

Retigabine and gabapentin restore channel function and neuronal firing of an epilepsy-associated dominant-negative <i>KCNQ5</i> variantSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.